Summary

Overview
Global Underactive Bladder Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
The trend such as the shift towards personalized medicine due to its advances in genetics and biomarker research enables in development of targeted therapies is expected to dominate the global underactive bladder treatment market.
The global underactive bladder treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such shift towards non-pharmacological treatments.
Furthermore, the rising prevalence of diabetes, increasing aging population, growing prevalence of neurological disorders such as multiple sclerosis and parkinson's disease, increasing number of clinical trials are driving up the underactive bladder treatment market size. The growing research activities for treating disease using underactive bladder treatment approach and presence of establish biopharmaceutical and pharmaceutical companies are some of the factors in demand from North America regions with significant competitors like Sanofi, Wellona Pharma, Accord-UK Ltd, AbbVie, and others actively operating in the market.
Dynamics
The Rising Geriatric Population to Drive the Growth of the Underactive Bladder Treatment Market
The growing number of elderly population is expected to drive the demand for underactive bladder treatment market. Both overactive and underactive bladder disorders become more prevalent with aging, result in a reduction in bladder emptying, and are responsible for increased morbidity, reduced quality of life, and rising healthcare expenses in an aging population.
For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion. Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion).
Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 billion. As geriatric population increases the demand for effective treatments is likely to happen. Thus, owing to the above factors the market is expected to drive over the forecast period..
The Growing Prevalence of Neurological Disorders will Drive the Underactive Bladder Treatment Market Growth
The growing prevalence of neurological conditions is expected to drive the underactive bladder market due to higher prevalence of multiple sclerosis, and parkinson's disease. For instance, according to World Health Organization 2023 report, parkinson's disease (PD) has more than doubled in the previous 25 years. In 2019, more than 8.5 million people were estimated to be affected by parkinson's disease worldwide.
Urinary dysfunction can be caused by parkinson's disease, including issues with urgency, frequency, and trouble emptying the bladder. Urinary abnormalities occur as a result of parkinson's disease because the disease affects the nerves that control the bladder, which holds and empties urine. Urinary changes might occur when bladder signals are not working properly.
Moreover, bladder problems may occur in both areas, including urine storage and emptying, and bladder emptying impairment is a less common but still concerning part of urinary dysfunction in parkinson's. Thus, owing to the above factors the market is expected to dominate the market over the forecast period.
The Rise in Funding for Research to Combact with Urinary Bladder Problems will Drive the Underactive Bladder Treatment Market Growth
The underactive bladder treatment market is expected to expand due to increased investment committed toward managing urinary bladder disorders. For instance, according to Florida International University news article punlished on January 2023, states that researchers are using the funds to create a computational model that has the potential to transform treatments for lower urinary tract disorders. The study has received a significant $3 million funding from the National Institutes of Health for a period of five years.
Furthermore, through this model, they want to identify the complicated connections between the neurological system and the urinary tract. Their primary focus is on addressing the issues caused by underactive bladders, a common lower urinary tract problem with few therapeutic choices.
These underactive bladders occur because of a result of a variety of circumstances, including aging, neurological diseases, and Parkinson's disease. The team aims to restore normal bladder function by using targeted electric stimulation of certain nerves. Thus, owing to the above factors will help to develop innotive, less invasive and effective treatment to drive the market over the forecast period.
The Side Effects Associated with the Underactive Bladder Drugs Will Hamper the Growth of the Market
The potential side effects associated with the medication for underactive bladder treatment is expected to face a major restraint. These adverse effects can vary greatly depending on the medicine. Anticholinergic medicines, for example, which are commonly used to treat overactive bladder but are also applicable to underactive bladder, can cause typical side effects such as dry mouth and constipation.
Furthermore, another medicine used to treat overactive bladder, duloxetine, can cause nausea, dry mouth, dizziness, constipation, insomnia, and fatigue. Therefore, owing to the side effects associated with drugs is expected to hampered the underactive bladder treatment market over the forecast period.
Segment Analysis
The global underactive bladder treatment market is segmented based on treatment type, route of administration, distribution channel and region.
Owing to the Wide Range of Options, the Pharmacotherapy Segment Accounted for Approximately 37.6% of the Underactive Bladder Treatment Market Share
In treatment type, the pharmacotherapy segment is expected to dominate the market, due to wide range of treatment choices contributing to its significance. Alpha-blockers, cholinesterase inhibitors, muscarinic agonists (such as bethanechol and carbachol), prostaglandin E2, and acotiamide are examples of these choices. These treatments address numerous underlying causes, giving patients a wide range of options for effective treatment.
Among this alpha blocker is widely used drug because of its larger impact on underactive bladder (UAB) treatment, particularly in patients with chronic bladder outlet obstruction (BOO). This effect extends to older people, particularly those with enlarged prostates, where Alpha-blockers relieve BOO-related symptoms and improve bladder emptying in cases of neurogenic lower urinary tract dysfunction and benign prostatic hyperplasia. The aplha blocker efficiency is also visible in females with voiding issues and subnormal maximal voiding velocities. A study found that combining Alpha-blockers with cholinergic medicines improved efficacy.
According to the EAU guidelines, alpha-blockers (tamsulosin, silodosin, and naftopidil) are useful medicines in patients with bladder outflow resistance, PVR, and autonomic dysreflexia. As a result, alpha-blockers should be examined for the initial phase in patients with chronic retention and UAB. Thus, due to wider options and effectiveness the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Rising Prevalence of Diabetes
North America, particularly the U.S., dominates the global underactive bladder treatment market due to growing prevalence of diabetes, and high research activities by major organization in the region. Diabetes can cause bladder dysfunction, including both overactive and underactive bladder. Urination dysfunction has long been a problem associated with diabetes, and bladder problems can often be more severe in people with diabetes.
For instance, according to American Diabetes Association report of 2022, approximately 37.3 million Americans, or 11.3% of the population had diabetes in 2019. About 283,000 people aging below 20 were diagnosed with diabetes in America. Furthermore, every year 1.4 million Americans are diagnosed with diabetes. Thus, owing to above factors the region is expected to grow over the forecast period.
Competitive Landscape
The major global players in the underactive bladder treatment market include Sanofi, Wellona Pharma, Accord-UK Ltd, AbbVie, Bausch Health Companies Inc., Éclat Pharmaceuticals, L.L.C., Chemo Biological, Alvogen, Hikma Pharmaceuticals PLC, Camber Pharmaceuticals, Inc., and among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had an impact on the underactive bladder treatment market since it has the potential to interfere with lower urinary tract function, resulting in underactive bladder as an outcome. COVID-19 has been linked to incomplete bladder emptying, urine retention, and higher bladder compliance in studies. While information on irritative urine symptoms is equivocal, survivors may experience respiratory muscle deficits that affect pelvic floor muscles.
Medical practitioners emphasize that COVID-19 has an effect on several internal systems, including the bladder, with symptoms such as fatigue and swelling noted. As a result of the pandemic's impact on underactive bladder, persons having urine symptoms post-COVID-19 require early medical attention, demanding extensive medical programs to address the virus's consequences on urological health.
By Treatment Type
• Pharmacotherapy
o Alpha-blockers
o Cholinesterase inhibitors
o Muscarinic agonists
o Prostaglandin E2
o Acotiamide
• Surgical Methods
o Sacral nerve stimulation–electrical stimulation
o Others
• Stem Cell and Gene Therapies
By Route of Administration
• Oral
• Parenteral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On January 10, 2023, Florida International Univeristy (FIU) received $3 million NIH grant to research on how electric stimulation can solve bladder issues. The researchers want to understand how electric stimulation of certain specific nerves could help people struggling with underactive bladders.
DMI Opinion
The global underactive bladder treatment market is expected to grow over the forecast period. An essential growing component for the growth is trend toward personalized medicine, which is being driven by genetics and biomarker research. Non-pharmacological treatments, as well as factors such as rising diabetes prevalence, aging population, neurological disorders, and expanded clinical studies, are driving the market's growth.
Additionally, funding for computational models at Florida International University emphasizes innovation. Potential pharmacological side effects, on the other hand, limit growth. The expanding elderly population and the rising number of neurological diseases both contribute to the market's growth. Sanofi, Wellona Pharma, and AbbVie are all active competitors. Notably, the effect of COVID-19 on underactive bladder emphasizes the importance of holistic healthcare interventions.
Why Purchase the Report?
• To visualize the global underactive bladder treatment market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of underactive bladder treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global underactive bladder treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents